MedTrace Logo

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

NCT02922231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2021-05-05

No results posted yet for this study

Summary

Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea.

Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.

Conditions

  • Hemophilia B

Interventions

BIOLOGICAL

RIXUBIS

Recombinant Factor IX (rFIX) for intravenous use

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-06
Primary Completion
2019-04-04
Completion
2019-04-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922231 on ClinicalTrials.gov